Skye Bioscience signs up to $22 million equity line with Redmile affiliate
On August 21, 2026, Skye Bioscience entered a Securities Purchase Agreement with an affiliate of Redmile Group under which the company can sell up to $22,000,000 of its common stock over three years, subject to conditions. The deal is tied to the proposed acquisition of Redx Pharma Limited and a related private placement, and the share sales would add to the number of shares outstanding.
Key points
- Equity line of up to $22,000,000, reduced by any amount the funded PIPE exceeds $103,000,000; no shares are sold if the funded PIPE amount reaches $125,000,000 or more
- Monthly sales capped at $2,000,000 of shares, priced at the lesser of the PIPE price and market price, with a floor 10% below the PIPE price
- Warrant issued at closing to purchase shares equal to $5,000,000 divided by the PIPE price, exercisable from January 1, 2027 to January 1, 2030
- Share issuances capped at 19.99% of outstanding common stock absent stockholder approval; company must file a resale registration statement within 10 business days of the closing date
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.